Skip to main content
Eutilex Co.,Ltd. logo

Eutilex Co.,Ltd. — Investor Relations & Filings

Ticker · 263050 ISIN · KR7263050007 KO Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2023-03-16 AGM Information
Country KR South Korea
Listing KO 263050

About Eutilex Co.,Ltd.

https://www.eutilex.com/en/

Eutilex Co., Ltd. is a biotechnology company focused on the research and development of immunotherapeutics for cancers and autoimmune diseases. The company's core approach involves selecting targets that enhance or suppress human immune responses. Its pipeline is centered on three primary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Key development programs include adoptive T-cell therapies, such as those based on 4-1BB cytotoxic T lymphocytes (CTL), and various immunomodulatory antibody therapeutics designed to treat a range of incurable diseases.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a 'General Meeting of Shareholders' (주주총회소집결의) for the company Eutilex. It details the date, location, and agenda items (such as financial statement approval, director appointments, and business purpose changes) for the upcoming Annual General Meeting. This document is a standard proxy-related filing used to inform shareholders of the meeting details and solicit their participation/votes. In the context of the provided categories, this fits the 'Proxy Solicitation & Information Statement' (PSI) classification.
2023-03-16 Korean
[기재정정]주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a regulatory filing from Eutilex regarding the rescheduling of their Annual General Meeting (AGM) to a 'concentrated date' (a date where many companies hold their AGMs). It explains the reason for the change in date and provides updated scheduling information. Since this is a regulatory notification regarding meeting logistics and does not fit into specific categories like proxy solicitation or voting results, it is classified as a general regulatory filing.
2023-03-16 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) which includes a 'Correction Report' (정정신고) regarding the date, location, and agenda items of the meeting. This document serves as the official proxy materials sent to shareholders to inform them of the upcoming meeting and request their votes. According to the provided definitions, this falls under 'Proxy Solicitation & Information Statement' (PSI).
2023-03-16 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and contains detailed information regarding a shareholder meeting, including the agenda, voting procedures, and proxy solicitation details. This document is a formal filing sent to shareholders to request their votes for an upcoming meeting, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2023-03-16 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal announcement titled '감사보고서 제출' (Submission of Audit Report) filed by Eutilex. It provides a summary of financial data, audit opinions, and key financial metrics (assets, liabilities, profit/loss) for the current and previous fiscal years. According to the 'Menu vs Meal' rule, this is a short, structured announcement summarizing the audit results rather than the full, multi-page audit report itself. Therefore, it is classified as a Report Publication Announcement (RPA). FY 2022
2023-03-15 Korean
투자판단관련주요경영사항(EU103(항VSIG4 항체치료제) 고형암 대상 제1상 임상시험계획서(IND) 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Eutilex regarding the approval of a Phase 1 clinical trial (IND) for their drug candidate EU103. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market (KIND system). Since it is a specific regulatory announcement regarding clinical trial status and does not fit into the other specialized categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2023-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.